Cervavac WHO Prequalification: What Serum Institute's HPV Vaccine Milestone Means
Serum Institute of India's Cervavac, a quadrivalent HPV vaccine for girls and boys aged 9 to 26, has received WHO prequalification, according to reports published on 5 and 6 October 2026. This post covers what the status means, the vaccine's profile, and which facts are worth revising.
On this page
Cervavac, the quadrivalent human papillomavirus (HPV) vaccine developed by Serum Institute of India in Pune, has received World Health Organization (WHO) prequalification. This matters because prequalification is the quality check that lets a vaccine be considered for procurement by United Nations agencies and other international public health programmes. It is a step towards wider global supply, not a guarantee of any particular order.
What happened and when
Two supplied reports carry the news. Deccan Herald published its report on 5 October 2026 at 10:47 IST, and GKToday published its post on 6 October 2026. Neither supplied text gives the exact date of the WHO decision, so treat 5 and 6 October as publication dates, not as the date of prequalification itself. As of 6 October 2026 the prequalification is reported as received, so it is a completed event. The evidence names no scheduled follow-up event.
What WHO prequalification means
WHO prequalification is a quality assessment process for medicines, vaccines and diagnostics. Its practical value is access to international procurement: UN agencies and global health programmes can consider prequalified products. The supplied evidence does not say which agencies or countries will buy Cervavac, in what quantities, or at what price.
A note on wording
Deccan Herald's headline calls the decision a "safety nod for global distribution". GKToday describes prequalification more precisely, as a quality assessment tied to procurement eligibility. For exam notes, "WHO prequalification" is the safer term.
Cervavac at a glance
| Feature | Reported detail |
|---|---|
| Developer | Serum Institute of India, Pune |
| Type | Quadrivalent HPV vaccine, protecting against four HPV types |
| Targeted HPV types | 6, 11, 16 and 18 |
| Indicated age group | Girls and boys aged nine through 26 years |
| Use | Prevention of HPV-related cancers and genital warts linked to the targeted types |
| Indian launch | 24 January 2023, after approval by the Drugs Controller General of India |
Why "gender-neutral" matters
GKToday calls Cervavac India's first indigenously developed gender-neutral quadrivalent HPV vaccine. In this context, gender-neutral means it is indicated for both girls and boys, not for one sex only.
The four HPV types
According to GKToday, types 16 and 18 are linked with several cancers, while types 6 and 11 are linked with genital warts. This split is easy to turn into a revision point.
Who developed it
GKToday says Cervavac was developed in collaboration with the Department of Biotechnology, the Biotechnology Industry Research Assistance Council (BIRAC), the WHO International Agency for Research on Cancer and the Bill & Melinda Gates Foundation. The evidence does not describe each partner's specific role.
Why it matters for India
Deccan Herald cites the WHO GLOBOCAN 2022 report: India records over 1,20,000 new cervical cancer cases and nearly 80,000 deaths each year, the highest death toll worldwide. That is the public health backdrop for an HPV vaccine. The evidence does not say how this prequalification will change vaccination coverage inside India.
GKToday also reports that this is the 32nd WHO prequalification received by Serum Institute of India for its products and biologicals, and that Cervavac expands India's presence in the global vaccine supply chain. The 32nd-prequalification figure comes from that single source.
Exam-relevant points
This is a Science and Technology and health current-affairs topic. Nothing here suggests a question will appear in any exam. These are the points that are supported and easy to revise:
- Cervavac is described as India's first indigenously developed gender-neutral quadrivalent HPV vaccine.
- It was developed by Serum Institute of India, based in Pune, Maharashtra.
- It targets HPV types 6, 11, 16 and 18.
- WHO prequalification helps UN agencies and international programmes consider a vaccine for procurement.
- It was launched in India on 24 January 2023 after approval by the DCGI.
What the evidence does not tell us
- The exact date of the WHO prequalification decision.
- Any statement from WHO or Serum Institute, since only two news-style reports were supplied and Deccan Herald's text is limited to its headline and the cancer statistic.
- Dosing schedule, price, supply volumes or the countries that may procure the vaccine.
FAQ
Is Cervavac only for girls?
No. GKToday reports that it is indicated for girls and boys aged nine through 26 years.
Does prequalification mean the vaccine has already been bought internationally?
No such purchase is reported in the supplied evidence. Prequalification allows the vaccine to be considered for procurement by UN agencies and international programmes.
Which HPV types does Cervavac target?
Types 6, 11, 16 and 18.
Sources & Further Reading
| Document / Website | Link |
|---|---|
| Serum Institute’s Cervavac Gets WHO Prequalification – GKToday | Open Serum Institute’s Cervavac Gets WHO Prequalification – GKToday ↗www.gktoday.in |
| HPV vaccine: Serum Institute indigenously developed Cervavac gets WHO safety nod | Open HPV vaccine: Serum Institute indigenously developed Cervavac gets WHO safety nod ↗www.deccanherald.com |
| CERVAVAC Quadrivalent Human Papillomavirus (Serotype 6, 11, 16 & 18) Vaccine Recombinant 1 NAME OF THE MEDICINAL PRODUCT Suspension for | Open CERVAVAC Quadrivalent Human Papillomavirus (Serotype 6, 11, 16 & 18) Vaccine Recombinant 1 NAME OF THE MEDICINAL PRODUCT Suspension for ↗cdsco.gov.in |